
Cupid Q1 FY27 Results: Revenue Rs 154 Cr, PAT Rs 44 Cr and Key Highlights
Cupid Q1 FY27 results declared August 7, 2026. Revenue Rs 154 Cr (+158.70% YoY). PAT Rs 44 Cr (+194.18% YoY). CMP Rs 262.13 (-0.18%).
Updated: 10 Aug 2026 • 12:11 pm
Posted by:

Cupid Q1 FY27 results were announced on August 7, 2026, consolidated. Revenue grew +158.70% YoY to Rs 154 Cr from Rs 59 Cr in Q1 FY26. The broader BSE Healthcare index reflected mixed sentiment during the quarter.
Operating profit stood at Rs 58 Cr (+285.83% YoY). PAT came in at Rs 44 Cr (+194.18% YoY), offering a comprehensive view of how Cupid is navigating the current healthcare environment.
Click Here – Get Free Investment Predictions
Cupid Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| Cupid Revenue | 154 | 59 | +158.70% |
| Operating Profit | 58 | 15 | +285.83% |
| Net Profit (PAT) | 44 | 15 | +194.18% |
| Reporting Basis | Consolidated | ||
Cupid Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
Cupid Q1 FY27 results reflect exceptional fundamentals across key financial metrics. Revenue momentum stayed robust with the top line reaching Rs 154 Cr for the April to June 2026 quarter.
Operating profit expanded +285.83% YoY to Rs 58 Cr. This indicates improving cost efficiency and better product mix.
PAT of Rs 44 Cr marks a +194.18% YoY movement in Cupid Q1 FY27 results. Investors monitoring Cupid Q1 FY27 results will note this as a key FY27 performance milestone.
Key Business Factors in Cupid Q1 FY27 Results
Revenue Expansion Driving Top-Line Growth
Cupid Q1 FY27 results show top-line strength with revenue growing +158.70% YoY to Rs 154 Cr from Rs 59 Cr in Q1 FY26. Order execution momentum and market share gains in the Healthcare segment fuelled this expansion.
Operating Leverage and Margin Improvement
Operating profit in Cupid Q1 FY27 results improved +285.83% YoY to Rs 58 Cr, reflecting better cost control, improving product mix, and operating leverage as the company scales volumes.
PAT Performance and Profitability Trend
Net profit (PAT) in Cupid Q1 FY27 results stood at Rs 44 Cr ((+194.18% YoY)). Improving PAT trajectory signals strengthening financial health.
Dividend Details
No dividend was announced alongside Cupid Q1 FY27 results. The company is likely channelling earnings toward business reinvestment and working capital needs.
FY27 Outlook for Cupid
Cupid is well-positioned to sustain growth momentum through FY27, backed by order visibility, sector tailwinds, and operational improvements. Management guidance points to continued expansion in the healthcare segment with a focus on margin improvement. Investors tracking Cupid Q1 FY27 results should consult a SEBI-registered financial advisor before making investment decisions.
Cupid Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track Cupid live price and get daily stock recommendations.
Cupid shares were trading lower at Rs 262.13 (-0.18%) on August 7, 2026, reflecting investor sentiment on the Cupid Q1 FY27 results and near-term sector outlook. The CMP of Rs 262.13 on the results date reflects broader market and sector sentiment in the healthcare space.
Key Risks for Cupid
Sector-Specific Risks
Rising operational costs and competition from large hospital chains limit margin upside.
Valuation and Earnings Risk
Valuation risk if quarterly growth momentum fails to sustain over the next two to three quarters.
Operational and Financial Risk
Subsidiary-level losses or underperforming overseas operations could drag consolidated PAT lower.
Conclusion
Cupid Q1 FY27 results reflect exceptional performance with revenue at Rs 154 Cr and PAT at Rs 44 Cr on a Consolidated basis. Operating leverage and sector tailwinds will determine the FY27 growth trajectory. Investors should review management commentary and sector developments before taking positions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Cupid Q1 FY27 Results
When were Cupid Q1 FY27 results declared?
Ans. Cupid Q1 FY27 results were declared on August 7, 2026, covering the April to June 2026 quarter on a Consolidated basis.
What was Cupid revenue in Q1 FY27?
Ans. Cupid Q1 FY27 results show revenue of Rs 154 Cr, +158.70% compared to Rs 59 Cr in Q1 FY26.
What was Cupid PAT in Q1 FY27?
Ans. Net profit in Cupid Q1 FY27 results was Rs 44 Cr, +194.18% year-on-year.
Did Cupid declare a dividend in Q1 FY27?
Ans. No dividend was announced alongside Cupid Q1 FY27 results. Check the official NSE and BSE announcements for future dividend declarations.
What is the FY27 outlook for Cupid?
Ans. Management has guided revenue growth and margin improvement for FY27. Sector trends and order visibility will be key monitorables for investors.
How did Cupid stock react to Q1 FY27 results?
Ans. Cupid shares were trading lower at Rs 262.13 (-0.18%) on August 7, 2026 following the Cupid Q1 FY27 results. Always consult a SEBI-registered financial advisor before acting on stock price movements.
Recent Articles

Delhivery vs Mahindra Logistics: Share Price, Comparison and Key Differences
10 August 2026

Tatva Chintan Pharmatec vs Laxmi Organic Industries: Share Price, Comparison and Key Differences
10 August 2026

Titan Company vs United Spirits: Share Price, Comparison and Key Differences
10 August 2026

CG Power and Industrial Solutions vs Thermax: Share Price, Comparison and Key Differences
10 August 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Delhivery vs Mahindra Logistics: Share Price, Comparison and Key Differences
Tatva Chintan Pharmatec vs Laxmi Organic Industries: Share Price, Comparison and Key Differences
Titan Company vs United Spirits: Share Price, Comparison and Key Differences
CG Power and Industrial Solutions vs Thermax: Share Price, Comparison and Key Differences
Glenmark Pharmaceuticals vs Strides Pharma Science: Share Price, Comparison and Key Differences

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





